In a groundbreaking study published in Science, researchers have embarked on a significant initiative to genetically profile cancers in domestic cats. This pioneering work aims to enhance our understanding of cancer in both felines and humans, while simultaneously establishing a valuable open resource for future feline oncology research.
Cancer remains a leading cause of illness and mortality in cats, yet the genetic underpinnings of these diseases have been largely unexplored. Dr. Geoffrey Wood, a pathobiology professor at the University of Guelph and co-senior author of the study, emphasized, "Despite the prevalence of domestic cats as pets, knowledge about the genetics of their cancers has been minimal until now."
Genetic Links Between Cat and Human Tumors
The research team analyzed tumor samples from approximately 500 cats across five countries, uncovering genetic mutations that play a role in cancer development. Remarkably, many of the genes identified are also implicated in cancers affecting humans and dogs. One significant discovery was the mutations associated with aggressive mammary cancers in cats.
The FBXW7 gene emerged as the most frequently altered in feline mammary tumors, with mutations found in over half of the samples examined. In human breast cancer, FBXW7 mutations correlate with poorer prognoses, mirroring the outcomes observed in cats.
Moreover, researchers noted genetic similarities in cancers affecting various systems, including the blood, bones, lungs, skin, gastrointestinal tract, and central nervous system. Given that cats often share living spaces with their owners, some cancer risks may arise from shared environmental factors.
"This research can deepen our understanding of cancer development in both cats and humans, how environmental factors influence cancer risk, and potentially lead to innovative prevention and treatment strategies," Wood remarked.
Promising Chemotherapy Insights
Encouragingly, the study revealed that certain chemotherapy drugs exhibited enhanced efficacy in treating cat mammary tumors with the mutated FBXW7 gene. While these findings were derived from tissue samples, they suggest new avenues for breast cancer treatment in both animals and humans.
Dr. Sven Rottenberg, co-senior author from the University of Bern, noted the unprecedented scale of this research, stating, "Access to such a vast collection of donated tissues allowed us to evaluate drug responses across various tumor types like never before."
Bailey Francis, co-first author at the Wellcome Sanger Institute, highlighted the potential benefits for canine health as well, stating, "Cross-disciplinary knowledge sharing can yield benefits for all species."
One Medicine: Bridging Human and Animal Health
This international collaboration involved researchers from the Wellcome Sanger Institute, Ontario Veterinary College at the University of Guelph, the University of Bern, among others. They sequenced DNA from previously collected veterinary diagnostic tissue samples. The findings indicate that treatments effective in humans could be tested in cats, and insights gained from feline cancer trials could inform future human clinical research.
This collaborative approach, known as One Medicine, fosters the exchange of knowledge between veterinary and medical researchers to enhance health outcomes across species. Dr. Louise Van Der Weyden, senior author at the Wellcome Sanger Institute, expressed optimism about the future of feline cancer care, stating, "We are poised to advance toward precision feline oncology, ultimately aligning with the diagnostic and therapeutic options available for dogs and, one day, humans."
The research was supported by organizations including the EveryCat Health Foundation, CVS Group, Wellcome, and the Natural Sciences and Engineering Research Council of Canada.